Validation of the lung inmune prognostic (LIPI) index in first-line immunotherapy treatment of small cell lung carcinoma

被引：0

作者：

Cruz Castellanos, P. ^{[1
]}

Gutierrez Sainz, L. ^{[2
]}

Fernandez Franco, L. ^{[3
]}

Rogado, J. ^{[4
]}

Mielgo Rubio, X. ^{[5
]}

Collazo Lorduy, A. ^{[6
]}

Riesco Montes, B. ^{[7
]}

Traseira Puchol, C. ^{[8
]}

Simon, S. ^{[9
]}

Falagan Martinez, S. ^{[10
]}

Chara Velarde, L. E. ^{[11
]}

Martin Fernandez, A. M. ^{[12
]}

Cabezon Gutierrez, L. ^{[13
]}

Lopez Martin, A. ^{[14
]}

Sanchez Sanchez, J. L. ^{[15
]}

Cerezo Gonzalez, S. ^{[16
]}

Viana, A. ^{[17
]}

Munoz-Rodriguez, J. R. ^{[18
]}

机构：

[1] Hosp Univ Cuidad Real, Dept Med Oncol, Ciudad Real, Spain

[2] Hosp Univ La Paz, Dept Med Oncol, Madrid, Spain

[3] Hosp Virgen Salud, Dept Oncol, Toledo, Spain

[4] Hosp Univ Infanta Leonor, Dept Med Oncol, Madrid, Spain

[5] Hosp Univ Fdn Alcorcon, Dept Med Oncol, Madrid, Spain

[6] Univ Hosp Puerta Hierro Majadahonda, Oncol Med, Majadahonda, Spain

[7] Complejo Hosp Univ Albacete, Dept Oncol, Albacete, Spain

[8] Hosp Henares, Dept Med Oncol, Coslada, Spain

[9] Hosp Virgen Cruz Cuenca, Dept Med Oncol, Hosp Gen Virgen Luz, Cuenca, Spain

[10] Hosp Univ Infanta Sofia, Dept Med Oncol, San Sebastian Los Reyes, Spain

[11] Hosp Univ Guadalajara, Dept Med Oncol, Guadalajara, Spain

[12] Hosp Henares, Dept Med Oncol, Coslada, Spain

[13] Hosp Univ Torrejon, Dept Med Oncol, Torrejon De Ardoz, Spain

[14] Hosp Univ Severo Ochoa, Dept Med Oncol, Madrid, Spain

[15] Hosp Gen Almansa, Dept Med Oncol, Almansa, Spain

[16] Hosp Gen Mancha Ctr, Med Oncol, Alcazar De San Juan, Spain

[17] Gen Hosp Nuestra Senora Prado, Med oncol, Toledo, Spain

[18] Hosp Gen Univ Ciudad Real, Med Oncol, Ciudad Real, Spain

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1900

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1809P

引用

页码：S1073 / S1073

页数：1

共 50 条

[1] Lung immune prognostic index (LIPI) as a prognostic factor in patients with extensive-stage small cell lung cancer treated with first-line chemoimmunotherapy
Herranz-Bayo, Elena
Chara-Velarde, Luis Enrique
Cassinello-Espinosa, Javier
Gimeno-Ballester, Vicente
Artal-Cortes, Angel
Moratiel-Pellitero, Alba
Alcacera-Lopez, Arancha
Navarro-Exposito, Fatima
Riesco-Montes, Blanca
Clemente-Andujar, Manuel
CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, : 1484 - 1492
[2] Applicability of lung immune prognostic index (LIPI) to predict efficacy of first-line pembrolizumab in advanced non-small cell lung cancer (NSCLC)
Mielgo Rubio, X.
Gomez Rueda, A.
Antonanzas, M.
Falagan, S.
Nunez, J. A.
Pena, A. M. Sanchez
Gomez-Barreda, I.
Martinez Moreno, E.
Cerezo Gonzalez, S.
Cabezon Gutierrez, L.
Sanchez Torres, J. M.
Jimenez Munarriz, B. E.
Cervera, R.
Pangua Mendez, C.
Calles Blanco, A.
Lopez Martin, A.
Lopez Castro, R.
Sotelo Lezama, M. J.
Perez Fernandez, E.
Cruz, P.
ANNALS OF ONCOLOGY, 2019, 30
[3] Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma
Carril-Ajuria, Lucia
Lavaud, Pernelle
Dalban, Cecile
Negrier, Sylvie
Gravis, Gwenaelle
Motzer, Robert J.
Chevreau, Christine
Tannir, Nizar M.
Oudard, Stephane
McDermott, David F.
Laguerre, Brigitte
Hammers, Hans J.
Barthelemy, Philippe
Plimack, Elizabeth R.
Borchiellini, Delphine
Gross-Goupil, Marine
Jiang, Ruiyun
Lee, Chung-Wei
de Silva, Heshani
Rini, Brian I.
Escudier, Bernard
Albiges, Laurence
EUROPEAN JOURNAL OF CANCER, 2024, 204
[4] External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer
Riedl, J. M.
Barth, D. A.
Foris, V.
Posch, F.
Mollnar, S.
Stotz, M.
Pichler, M.
Stoeger, H.
Absenger, G.
Olschewski, H.
Gerger, A.
ANNALS OF ONCOLOGY, 2019, 30
[5] External validation and longitudinal extension of the LIPI (lung immune prognostic index) for immunotherapy outcomes in advanced non-small cell lung cancer
Barth, D. A.
Riedl, J. M.
Foris, V.
Posch, F.
Mollnar, S.
Stotz, M.
Pichler, M.
Stoeger, H.
Absenger, G.
Olschewski, H.
Gerger, A.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 108 - 108
[6] Letter comments on: Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma
Rebuzzi, Sara Elena
Fornarini, Giuseppe
Banna, Giuseppe Luigi
Rescigno, Pasquale
Buti, Sebastiano
EUROPEAN JOURNAL OF CANCER, 2024, 205
[7] Chemo-immunotherapy as first-line treatment for small-cell lung cancer
Farid, Saira
Liu, Stephen V.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
[8] Clinical Effectiveness of First-Line Immunotherapy in Small Cell Lung Cancer
Lee, M.
Zhang, F.
Cheng, H.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S694 - S695
[9] First-Line Immunotherapy for Non-Small-Cell Lung Cancer
Reck, Martin
Remon, Jordi
Hellmann, Matthew D.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06) : 586 - +
[10] Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
Martinez, Pablo
Peters, Solange
Stammers, Timothy
Soria, Jean-Charles
CLINICAL CANCER RESEARCH, 2019, 25 (09) : 2691 - 2698

← 1 2 3 4 5 →